76 completed. 76 Phase 2, 24 Phase 1, 6 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 76 | Completed 76 |
| Phase 1 | 24 | Completed 24 |
| Phase 3 | 6 | Completed 6 |
Follow Lipidoses: new trials by email Literature Review of Lipidoses trials Research Report on Lipidoses
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase 2 Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral AZ-3102 in Patients With GM2 Gangliosidosis or Niemann-Pick Type C Disease AZ-3102 (Dose 1), Placebo, AZ-3102 (Dose 2) - GM2 Gangliosidosis, Niemann-Pick Disease, Type C | Phase 2 | Completed | Azafaros B.V. | 13 | 2023-04-24 | 2026-05-14 |
| ADX-629 Therapy for Sjogren-Larsson Syndrome ADX-629 - Sjogren-Larsson Syndrome | Phase 1 / Phase 2 | Completed | University of Nebraska | 8 | 2023-01-02 | 2026-05-05 |
| A Second-generation AI Based Therapeutic Regimen in Patients With Gaucher Disease Treated With Enzyme Replacement Therapy. Enzyme replacement therapy for Gaucher disease in combination with altus care application - Gaucher Disease Type 1 | Phase 2 | Completed | Hadassah Medical Organization | 5 | 2022-04-01 | 2023-09-22 |
| An Open-label Safety, Pharmacokinetic, and Efficacy Study of Miglustat for the Treatment of Subjects With Batten Ceroid Lipofuscinosis, Neuronal 3 (CLN3) Disease Miglustat 100 milligrams (mg) Oral Capsule - Batten Disease | Phase 1 / Phase 2 | Completed | Beyond Batten Disease Foundation | 6 | 2022-03-10 | 2025-09-09 |
| A Study to Evaluate Safety and Tolerability of Olipudase Alfa in Pediatric and Adult Participants With Acid Sphingomyelinase Deficiency (ASMD) Who Completed the DFI12712 or the LTS13632 Study in France Olipudase alfa - Acid Sphingomyelinase Deficiency | Phase 2 | Completed | Sanofi | 3 | 2021-11-18 | 2026-04-13 |
| N-Acetyl-L-Leucine for Niemann-Pick Disease, Type C (NPC) IB1001 - Niemann-Pick Disease, Type C | Phase 2 | Completed | IntraBio Inc | 33 | 2019-09-04 | 2023-11-28 |
| Dose-Ranging Study of ST-920, an AAV2/6 Human Alpha Galactosidase A Gene Therapy in Subjects With Fabry Disease (STAAR) ST-920 - Fabry Disease | Phase 1 / Phase 2 | Completed | Sangamo Therapeutics | 36 | 2019-07-23 | 2026-10-27 |
| N-Acetyl-L-Leucine for GM2 Gangliosidosis (Tay-Sachs and Sandhoff Disease) IB1001 - GM2 Gangliosidosis, Tay-Sachs Disease | Phase 2 | Completed | IntraBio Inc | 30 | 2019-06-07 | 2024-03-12 |
| A Study of Intrathecal SHP611 in Children With Metachromatic Leukodystrophy SHP611 - Metachromatic Leukodystrophy (MLD) | Phase 2 | Completed | Shire | 36 | 2019-05-13 | 2026-07-10 |
| Ambroxol Therapy for Patients With Type 1 Gaucher Disease and Suboptimal Response to Enzyme Replacement Therapy Ambroxol - Gaucher Disease, Type 1 | Phase 2 | Completed | Shaare Zedek Medical Center | 40 | 2019-03-01 | 2023-02-14 |
| Study of IV VTS-270 for Infantile Liver Disease Associated With Niemann-Pick Disease, Type C VTS-270 - Niemann-Pick Disease, Type C | Phase 1 / Phase 2 | Completed | Washington University School of Medicine | 4 | 2019-02-22 | 2026-01-05 |
| MGTA-456 in Patients With Inherited Metabolic Disorders Undergoing Hematopoietic Stem Cell Transplantation (HSCT) MGTA-456 - Inherited Metabolic Disorders (IMD) | Phase 2 | Completed | Magenta Therapeutics, Inc. | 8 | 2018-02-09 | 2021-11-03 |
| A Safety and Efficacy Study of Cryopreserved OTL-200 for Treatment of Metachromatic Leukodystrophy (MLD) OTL-200 - Lysosomal Storage Disease, Metachromatic Leukodystrophy | Phase 2 | Completed | Orchard Therapeutics | 10 | 2018-01-25 | 2026-03-16 |
| Safety and Efficacy of Intravenous Trappsol Cyclo (HPBCD) in Niemann-Pick Type C Patients Hydroxypropyl-beta-cyclodextrin - Niemann-Pick Disease, Type C1 | Phase 1 / Phase 2 | Completed | Cyclo Therapeutics, Inc. | 12 | 2017-03-20 | 2021-08-10 |
| Arimoclomol Prospective Study in Participants Diagnosed With Niemann-Pick Disease Type C arimoclomol, Placebo - Niemann-Pick Disease, Type C | Phase 2 / Phase 3 | Completed | ZevraDenmark | 50 | 2016-06-14 | 2024-11-29 |
| Gene Therapy For Children With Variant Late Infantile Neuronal Ceroid Lipofuscinosis 6 (vLINCL6) Disease AT-GTX-501 - Variant Late-Infantile Neuronal Ceroid Lipofuscinosis | Phase 1 / Phase 2 | Completed | Emily de los Reyes | 13 | 2016-05-01 | 2025-10-24 |
| A Safety, Tolerability, and Efficacy Study of BMN 190 in Pediatric Patients < 18 Years of Age With CLN2 Disease BMN 190 recombinant human tripeptidyl peptidase-1 (rhTPP1), Intracerebroventricular access device - Jansky-Bielschowsky Disease, Batten Disease | Phase 2 | Completed | BioMarin Pharmaceutical | 14 | 2016-01-22 | 2025-02-17 |
| Efficacy, Safety, Pharmacodynamic, and Pharmacokinetics Study of Olipudase Alfa in Patients With Acid Sphingomyelinase Deficiency placebo (saline), Olipudase alfa - Sphingomyelin Lipidosis | Phase 2 / Phase 3 | Completed | Genzyme, a Sanofi Company | 36 | 2015-12-18 | 2024-11-07 |
| VTS-270 to Treat Niemann-Pick Type C1 (NPC1) Disease Parts A/B: Adrabetadex, Parts A/B: Sham Control - Niemann-Pick Disease, Type C | Phase 2 / Phase 3 | Completed | Mandos LLC | 56 | 2015-10-01 | 2023-02-22 |
| Role of Oxidative Stress and Inflammation in Type 1 Gaucher Disease (GD1) N-acetylcysteine - Gaucher Disease Type 1 | Phase 2 | Completed | University of Minnesota | 33 | 2015-09-01 | 2026-02-18 |
Showing 20 of 76. Sign in to see all of them.
Fabry Disease (19) · Gaucher Disease (15) · Leukodystrophy, Metachromatic (12) · Niemann-Pick Disease, Type C (9) · Lysosomal Storage Diseases (8) · Neuronal Ceroid-Lipofuscinoses (8) · Wolman Disease (6) · Sandhoff Disease (5) · Tay-Sachs Disease (5) · Cholesterol Ester Storage Disease (4) · Gangliosidoses, GM2 (4) · Leukodystrophy, Globoid Cell (4) · Niemann-Pick Disease, Type A (4) · Niemann-Pick Diseases (4) · Stroke (4)
Congenital, Hereditary, and Neonatal Diseases and Abnormalities (76) · Nutritional and Metabolic Diseases (76) · Lipid Metabolism Disorders (75) · Lipid Metabolism, Inborn Errors (75) · Metabolic Diseases (75) · Genetic Diseases, Inborn (74) · Metabolism, Inborn Errors (73) · Nervous System Diseases (71) · Brain Diseases (64) · Central Nervous System Diseases (64) · Brain Diseases, Metabolic (63) · Brain Diseases, Metabolic, Inborn (63) · Lysosomal Storage Diseases, Nervous System (63) · Sphingolipidoses (61)
agalsidase alfa (7) · larazotide acetate (5) · migalastat (5) · Sebelipase alfa (4) · olipudase alfa (4) · 2-Hydroxypropyl-beta-cyclodextrin (3) · AT2101 (3) · Glucosylceramidase (3) · agalsidase beta (3) · cerliponase alfa (3) · miglustat (3) · Acetylcysteine (2) · Alemtuzumab (2) · Busulfan (2) · Cyclophosphamide (2)
Shire (10) · Amicus Therapeutics (8) · Genzyme, a Sanofi Company (8) · National Institute of Neurological Disorders and Stroke (NINDS) (5) · Alexion Pharmaceuticals, Inc. (4) · BioMarin Pharmaceutical (3) · Masonic Cancer Center, University of Minnesota (3) · Protalix (3) · Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) (2) · IntraBio Inc (2) · Orchard Therapeutics (2) · The Hospital for Sick Children (2) · Actelion (1) · Aldeyra Therapeutics, Inc. (1) · Assistance Publique - Hôpitaux de Paris (1)
United States (54) · United Kingdom (28) · France (19) · Germany (15) · Italy (13) · Australia (10) · Canada (10) · Israel (10) · Spain (10) · Brazil (9) · Poland (6) · Belgium (5) · Denmark (5) · Czechia (4) · Japan (4)
Paul Orchard, MD (3) · Forbes D Porter, M.D. (2) · An N. Dang Do, MD, PhD (1) · Ari Zimran (1) · Caroline Sevin, MD-PhD (1) · Claudia Chiriboga, Assoc. Prof. MD (1) · David Jacoby (1) · Erika F Augustine, MD (1)
PMID 27657681, PMID 21586746, PMID 23176611, PMID 23348766, PMID 29688815, PMID 33482890, PMID 33980287, PMID 34349180, PMID 36481125, PMID 38101904, PMID 38776275, PMID 40267426, PMID 18346516, PMID 19595619, PMID 20299511, PMID 20439622, PMID 20713962, PMID 23339116, PMID 23474038, PMID 23860343, PMID 24014509, PMID 24816856, PMID 24835462, PMID 25425121, PMID 25758611, PMID 26252393, PMID 27289174, PMID 27307708, PMID 27866808, PMID 29305734, PMID 30834538, PMID 31184505, PMID 32620536, PMID 32657505, PMID 32792226, PMID 33332761, PMID 33875845, PMID 34387740, PMID 34389161, PMID 34418116, PMID 35065785, PMID 35442238, PMID 36456200, PMID 36739645, PMID 37098529, PMID 37171121, PMID 37670901, PMID 38042851, PMID 39774103, PMID 40525490
2015 (2), 2005 (1), 2014 (1), 2017 (1), 2018 (1), U01HD090845 (1), U54NS065768 (1)